GOSS News and Press, Gossamer Bio Inc. From 11/08/21

Gossamer Bio (NASDAQ:GOSS): Q3 GAAP EPS of -$0.80 misses by $0.02. Cash, cash equivalents and marketable securities totaled $366 million as of September 30, 2021. Press Release For further details see: Gossamer Bio EPS misses by $0.02

- Topline Results from Ongoing Phase 2 TORREY Study of Seralutinib in Patients with PAH Now Expected in Second Half of 2022, Due to COVID-19-Related Delays - - Phase 2 SHIFT-UC Study of GB004 in Patients with UC has Completed Enrollment with 12-Week Topline Results Expected in...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its third quarter 2021 fina...

Shares of Gossamer Bio have rebounded some 75% off their lows set in mid-July and have pivoted away from its failed asthma asset GB001. Merck’s $11 billion overture for Acceleron and its PAH candidate (sotatercept), in addition to positive commentary from Piper have also booste...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the addition of two CNS-penetrant Bruton’...

Piper Sandler Technical Market Strategist Craig. W. Johnson is out with his latest quarterly Alpha Alignment Report, which screens 900 stocks for a host of fundamental and technical factors. Along with the headline Alpha Alignment Index, the report also screens for an equal-weighted Short Squ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast...

Gainers: Cellect Biotechnology (NASDAQ:APOP) +24%, Keros Therapeutics (NASDAQ:KROS) +24%, Gossamer Bio (NASDAQ:GOSS) +17%, Seelos Therapeutics (NASDAQ:SEEL) +16%, DiaMedica Therapeutics (NASDAQ:DMAC) +9%. Losers: ASLAN Pharmaceuticals (NASDAQ:ASLN)...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that, Bryan Giraudo has been appointed Chief Op...

The following slide deck was published by Gossamer Bio, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Gossamer Bio, Inc. 2021 Q2 - Results - Earnings Call Presentation